Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy

Seventy-one patients with pathologic Stage B ( P 2 3 a N 0 ) transitional cell carcinoma (TCC) of the bladder underwent radical cystectomy alone without preoperative radiotherapy or perioperative chemotherapy between 1983 and 1987 and have been followed a median of fifty months. The five-year actuar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urology (Ridgewood, N.J.) N.J.), 1992, Vol.39 (1), p.12-16
Hauptverfasser: Wishnow, Kenneth I., Ayala, Alberto J., Keith Levinson, A., Logothetis, Christopher J., Johnson, Douglas E., Swanson, David A., Tenney, Denise M., Joseph Babaian, R., Grignon, David J., von Eschenbach, Andrew C., Ro, Jae Y.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 16
container_issue 1
container_start_page 12
container_title Urology (Ridgewood, N.J.)
container_volume 39
creator Wishnow, Kenneth I.
Ayala, Alberto J.
Keith Levinson, A.
Logothetis, Christopher J.
Johnson, Douglas E.
Swanson, David A.
Tenney, Denise M.
Joseph Babaian, R.
Grignon, David J.
von Eschenbach, Andrew C.
Ro, Jae Y.
description Seventy-one patients with pathologic Stage B ( P 2 3 a N 0 ) transitional cell carcinoma (TCC) of the bladder underwent radical cystectomy alone without preoperative radiotherapy or perioperative chemotherapy between 1983 and 1987 and have been followed a median of fifty months. The five-year actuarial survival and disease free survival rates were 82 percent and 77 percent, respectively, and only 13 patients (18%) have relapsed. Histologic parameters were evaluated as to prognostic impact; none correlated with disease-free survival rates although the presence of vessel involvement portended a worse disease free survival rate (68% versus 80%). During this same period, an additional 15 patients underwent radical cystectomy for pathologic Stage B disease but received adjuvant chemotherapy on the basis of vessel invasion. Their disease free survival rate at five years was 80 percent, comparable to the disease free survival rate for patients with vessel invasion treated by surgery alone (68%). Although the role of systemic chemotherapy in the management of invasive bladder cancer remains under investigation, it would appear that patients with Stage B TCC are best treated with radical cystectomy alone. Continued analysis of modern surgical results grouped by current pathologic staging criteria is needed to identify patients who have a relatively low risk of relapse and thus little need for additional therapeutic intervention. These results demonstrate that Stage P 2 3 a N 0 TCC of the bladder is highly curable by surgery.
doi_str_mv 10.1016/0090-4295(92)90033-S
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72727071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>009042959290033S</els_id><sourcerecordid>72727071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-f27b6092bdb475504348f20936f9f1ed27d8b9a5bb7e53f0bd8b20f591ed86fd3</originalsourceid><addsrcrecordid>eNp9kEtr3TAQhUVoSW-T_IMEtCrJwo0sW5a1KaShj0Agi5uuShB6jHJVbCuV5IL_feXc0O6CQGI458yMPoROa_KxJnV3SYggVUsFOxf0QhDSNNX2AG1qRnklhGBv0Oaf5R16n9IvQkjXdfwQHdac9rwXG7TbZvUI-DM-xz9diOM8KBxGnzPYhwuco5qSzz5MasAGhnKpaPwUxuJyWA_KWoh45x93w4LNHJUeAOsFR2W9WTNLymByGJdj9NapIcHJy3uEfnz9cn_9vbq9-3ZzfXVbmZbRXDnKdUcE1Va3nDHSNm3vKBFN54SrwVJuey0U05oDaxzRpaTEMVG0vnO2OUIf9n2fYvg9Q8py9GldXU0Q5iQ5LYfwuhjbvdHEkFIEJ5-iH1VcZE3kCliu9ORKTwoqnwHLbYmdvfSf9Qj2f2hPtOif9jqUT_7xEGUyHiYD1sdCQtrgXx_wF8stizg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72727071</pqid></control><display><type>article</type><title>Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wishnow, Kenneth I. ; Ayala, Alberto J. ; Keith Levinson, A. ; Logothetis, Christopher J. ; Johnson, Douglas E. ; Swanson, David A. ; Tenney, Denise M. ; Joseph Babaian, R. ; Grignon, David J. ; von Eschenbach, Andrew C. ; Ro, Jae Y.</creator><creatorcontrib>Wishnow, Kenneth I. ; Ayala, Alberto J. ; Keith Levinson, A. ; Logothetis, Christopher J. ; Johnson, Douglas E. ; Swanson, David A. ; Tenney, Denise M. ; Joseph Babaian, R. ; Grignon, David J. ; von Eschenbach, Andrew C. ; Ro, Jae Y.</creatorcontrib><description>Seventy-one patients with pathologic Stage B ( P 2 3 a N 0 ) transitional cell carcinoma (TCC) of the bladder underwent radical cystectomy alone without preoperative radiotherapy or perioperative chemotherapy between 1983 and 1987 and have been followed a median of fifty months. The five-year actuarial survival and disease free survival rates were 82 percent and 77 percent, respectively, and only 13 patients (18%) have relapsed. Histologic parameters were evaluated as to prognostic impact; none correlated with disease-free survival rates although the presence of vessel involvement portended a worse disease free survival rate (68% versus 80%). During this same period, an additional 15 patients underwent radical cystectomy for pathologic Stage B disease but received adjuvant chemotherapy on the basis of vessel invasion. Their disease free survival rate at five years was 80 percent, comparable to the disease free survival rate for patients with vessel invasion treated by surgery alone (68%). Although the role of systemic chemotherapy in the management of invasive bladder cancer remains under investigation, it would appear that patients with Stage B TCC are best treated with radical cystectomy alone. Continued analysis of modern surgical results grouped by current pathologic staging criteria is needed to identify patients who have a relatively low risk of relapse and thus little need for additional therapeutic intervention. These results demonstrate that Stage P 2 3 a N 0 TCC of the bladder is highly curable by surgery.</description><identifier>ISSN: 0090-4295</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/0090-4295(92)90033-S</identifier><identifier>PMID: 1728789</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - surgery ; Cystectomy - methods ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Survival Analysis ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - surgery</subject><ispartof>Urology (Ridgewood, N.J.), 1992, Vol.39 (1), p.12-16</ispartof><rights>1992</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-f27b6092bdb475504348f20936f9f1ed27d8b9a5bb7e53f0bd8b20f591ed86fd3</citedby><cites>FETCH-LOGICAL-c452t-f27b6092bdb475504348f20936f9f1ed27d8b9a5bb7e53f0bd8b20f591ed86fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0090-4295(92)90033-S$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,4010,27904,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1728789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wishnow, Kenneth I.</creatorcontrib><creatorcontrib>Ayala, Alberto J.</creatorcontrib><creatorcontrib>Keith Levinson, A.</creatorcontrib><creatorcontrib>Logothetis, Christopher J.</creatorcontrib><creatorcontrib>Johnson, Douglas E.</creatorcontrib><creatorcontrib>Swanson, David A.</creatorcontrib><creatorcontrib>Tenney, Denise M.</creatorcontrib><creatorcontrib>Joseph Babaian, R.</creatorcontrib><creatorcontrib>Grignon, David J.</creatorcontrib><creatorcontrib>von Eschenbach, Andrew C.</creatorcontrib><creatorcontrib>Ro, Jae Y.</creatorcontrib><title>Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>Seventy-one patients with pathologic Stage B ( P 2 3 a N 0 ) transitional cell carcinoma (TCC) of the bladder underwent radical cystectomy alone without preoperative radiotherapy or perioperative chemotherapy between 1983 and 1987 and have been followed a median of fifty months. The five-year actuarial survival and disease free survival rates were 82 percent and 77 percent, respectively, and only 13 patients (18%) have relapsed. Histologic parameters were evaluated as to prognostic impact; none correlated with disease-free survival rates although the presence of vessel involvement portended a worse disease free survival rate (68% versus 80%). During this same period, an additional 15 patients underwent radical cystectomy for pathologic Stage B disease but received adjuvant chemotherapy on the basis of vessel invasion. Their disease free survival rate at five years was 80 percent, comparable to the disease free survival rate for patients with vessel invasion treated by surgery alone (68%). Although the role of systemic chemotherapy in the management of invasive bladder cancer remains under investigation, it would appear that patients with Stage B TCC are best treated with radical cystectomy alone. Continued analysis of modern surgical results grouped by current pathologic staging criteria is needed to identify patients who have a relatively low risk of relapse and thus little need for additional therapeutic intervention. These results demonstrate that Stage P 2 3 a N 0 TCC of the bladder is highly curable by surgery.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - surgery</subject><subject>Cystectomy - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - surgery</subject><issn>0090-4295</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtr3TAQhUVoSW-T_IMEtCrJwo0sW5a1KaShj0Agi5uuShB6jHJVbCuV5IL_feXc0O6CQGI458yMPoROa_KxJnV3SYggVUsFOxf0QhDSNNX2AG1qRnklhGBv0Oaf5R16n9IvQkjXdfwQHdac9rwXG7TbZvUI-DM-xz9diOM8KBxGnzPYhwuco5qSzz5MasAGhnKpaPwUxuJyWA_KWoh45x93w4LNHJUeAOsFR2W9WTNLymByGJdj9NapIcHJy3uEfnz9cn_9vbq9-3ZzfXVbmZbRXDnKdUcE1Va3nDHSNm3vKBFN54SrwVJuey0U05oDaxzRpaTEMVG0vnO2OUIf9n2fYvg9Q8py9GldXU0Q5iQ5LYfwuhjbvdHEkFIEJ5-iH1VcZE3kCliu9ORKTwoqnwHLbYmdvfSf9Qj2f2hPtOif9jqUT_7xEGUyHiYD1sdCQtrgXx_wF8stizg</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>Wishnow, Kenneth I.</creator><creator>Ayala, Alberto J.</creator><creator>Keith Levinson, A.</creator><creator>Logothetis, Christopher J.</creator><creator>Johnson, Douglas E.</creator><creator>Swanson, David A.</creator><creator>Tenney, Denise M.</creator><creator>Joseph Babaian, R.</creator><creator>Grignon, David J.</creator><creator>von Eschenbach, Andrew C.</creator><creator>Ro, Jae Y.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1992</creationdate><title>Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy</title><author>Wishnow, Kenneth I. ; Ayala, Alberto J. ; Keith Levinson, A. ; Logothetis, Christopher J. ; Johnson, Douglas E. ; Swanson, David A. ; Tenney, Denise M. ; Joseph Babaian, R. ; Grignon, David J. ; von Eschenbach, Andrew C. ; Ro, Jae Y.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-f27b6092bdb475504348f20936f9f1ed27d8b9a5bb7e53f0bd8b20f591ed86fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - surgery</topic><topic>Cystectomy - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wishnow, Kenneth I.</creatorcontrib><creatorcontrib>Ayala, Alberto J.</creatorcontrib><creatorcontrib>Keith Levinson, A.</creatorcontrib><creatorcontrib>Logothetis, Christopher J.</creatorcontrib><creatorcontrib>Johnson, Douglas E.</creatorcontrib><creatorcontrib>Swanson, David A.</creatorcontrib><creatorcontrib>Tenney, Denise M.</creatorcontrib><creatorcontrib>Joseph Babaian, R.</creatorcontrib><creatorcontrib>Grignon, David J.</creatorcontrib><creatorcontrib>von Eschenbach, Andrew C.</creatorcontrib><creatorcontrib>Ro, Jae Y.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wishnow, Kenneth I.</au><au>Ayala, Alberto J.</au><au>Keith Levinson, A.</au><au>Logothetis, Christopher J.</au><au>Johnson, Douglas E.</au><au>Swanson, David A.</au><au>Tenney, Denise M.</au><au>Joseph Babaian, R.</au><au>Grignon, David J.</au><au>von Eschenbach, Andrew C.</au><au>Ro, Jae Y.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>1992</date><risdate>1992</risdate><volume>39</volume><issue>1</issue><spage>12</spage><epage>16</epage><pages>12-16</pages><issn>0090-4295</issn><eissn>1527-9995</eissn><abstract>Seventy-one patients with pathologic Stage B ( P 2 3 a N 0 ) transitional cell carcinoma (TCC) of the bladder underwent radical cystectomy alone without preoperative radiotherapy or perioperative chemotherapy between 1983 and 1987 and have been followed a median of fifty months. The five-year actuarial survival and disease free survival rates were 82 percent and 77 percent, respectively, and only 13 patients (18%) have relapsed. Histologic parameters were evaluated as to prognostic impact; none correlated with disease-free survival rates although the presence of vessel involvement portended a worse disease free survival rate (68% versus 80%). During this same period, an additional 15 patients underwent radical cystectomy for pathologic Stage B disease but received adjuvant chemotherapy on the basis of vessel invasion. Their disease free survival rate at five years was 80 percent, comparable to the disease free survival rate for patients with vessel invasion treated by surgery alone (68%). Although the role of systemic chemotherapy in the management of invasive bladder cancer remains under investigation, it would appear that patients with Stage B TCC are best treated with radical cystectomy alone. Continued analysis of modern surgical results grouped by current pathologic staging criteria is needed to identify patients who have a relatively low risk of relapse and thus little need for additional therapeutic intervention. These results demonstrate that Stage P 2 3 a N 0 TCC of the bladder is highly curable by surgery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1728789</pmid><doi>10.1016/0090-4295(92)90033-S</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-4295
ispartof Urology (Ridgewood, N.J.), 1992, Vol.39 (1), p.12-16
issn 0090-4295
1527-9995
language eng
recordid cdi_proquest_miscellaneous_72727071
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Aged
Aged, 80 and over
Carcinoma, Transitional Cell - mortality
Carcinoma, Transitional Cell - pathology
Carcinoma, Transitional Cell - surgery
Cystectomy - methods
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Staging
Retrospective Studies
Survival Analysis
Urinary Bladder Neoplasms - mortality
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - surgery
title Stage B ( [formula omitted]) transitional cell carcinoma of bladder highly curable by radical cystectomy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T18%3A51%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stage%20B%20(%20%5Bformula%20omitted%5D)%20transitional%20cell%20carcinoma%20of%20bladder%20highly%20curable%20by%20radical%20cystectomy&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Wishnow,%20Kenneth%20I.&rft.date=1992&rft.volume=39&rft.issue=1&rft.spage=12&rft.epage=16&rft.pages=12-16&rft.issn=0090-4295&rft.eissn=1527-9995&rft_id=info:doi/10.1016/0090-4295(92)90033-S&rft_dat=%3Cproquest_cross%3E72727071%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72727071&rft_id=info:pmid/1728789&rft_els_id=009042959290033S&rfr_iscdi=true